Small cell lung cancer
Small cell lung cancer (SCLC) accounts for about 20% of lung cancer. It is highly malignant, has a short doubling time, early and extensive metastasis, is sensitive to chemotherapy and radiotherapy, and has a high initial remission rate. However, it is very prone to secondary drug resistance and relapse. Treatment is mainly systemic chemotherapy.
-
Site of disease:
lung -
Infectious :
Not contagious -
Frequent population:
Middle-aged smokers are more likely to -
Related symptoms:
Fatigue cough shortness of breath weight loss
Related Drugs
Docetaxel Injection
Indication: 1. Docetaxel is suitable for the treatment of advanced or metastatic breast cancer after failure of previous chemotherapy. Unless it is clinically contraindicated, previous treatment should include anthracycline anticancer drugs. 2. Docetaxel is suitable for the treatment of advanced or metastatic non-small cell lung cancer after failure of chemotherapy based on cisplatin.
Manufacturer:
Shanghai SPH New ASIA Pharmaceutical Co., Ltd.
Docetaxel Injection
Indication: 1. Docetaxel is suitable for the treatment of advanced or metastatic breast cancer after failure of previous chemotherapy. Unless it is clinically contraindicated, previous treatment should include anthracycline anticancer drugs. 2. Docetaxel is suitable for the treatment of advanced or metastatic non-small cell lung cancer after failure of chemotherapy based on cisplatin.
Docetaxel Injection
Indication: 1. Docetaxel is suitable for the treatment of advanced or metastatic breast cancer after failure of previous chemotherapy. Unless it is clinically contraindicated, previous treatment should include anthracycline anticancer drugs. 2. Docetaxel is suitable for the treatment of advanced or metastatic non-small cell lung cancer after failure of chemotherapy based on cisplatin.
Manufacturer:
Sichuan Meida Kangjiale Pharmaceutical Co., Ltd.
Docetaxel Injection
Indication: 1. It is suitable for the treatment of locally advanced or metastatic breast cancer. 2. It is suitable for the treatment of locally advanced or metastatic non-small cell lung cancer, even after the failure of cisplatin-based chemotherapy.
Gemcitabine Hydrochloride for Injection
Indication: Suitable for the treatment of intermediate and advanced non-small cell lung cancer.
Manufacturer:
Qilu Pharmaceutical (Hainan) Co., Ltd.
Gemcitabine Hydrochloride for Injection
Indication: Suitable for the treatment of intermediate and advanced non-small cell lung cancer.
Gemcitabine Hydrochloride for Injection
Indication: Suitable for the treatment of intermediate and advanced non-small cell lung cancer.
Manufacturer:
Harbin Pharmaceutical Group Bioengineering Co., Ltd.
Gemcitabine Hydrochloride for Injection
Indication: Suitable for the treatment of intermediate and advanced non-small cell lung cancer.
Manufacturer:
Harbin Pharmaceutical Group Bioengineering Co., Ltd.
Gemcitabine Hydrochloride for Injection
Indication: Suitable for the treatment of intermediate and advanced non-small cell lung cancer.
Manufacturer:
Harbin Reputation Scale Pharmaceutical Co., Ltd.
Gemcitabine Hydrochloride for Injection
Indication: Non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer and other solid tumors.
Manufacturer:
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Related Ingredients